New approaches to diagnosis and classification of axial and peripheral spondyloarthritis, Curr Opin Rheumatol, vol.22, pp.375-380, 2010. ,
How should we diagnose spondyloarthritis according to the ASAS classification criteria: a guide for practicing physicians, Pol Arch Med Wewn, vol.120, pp.452-457, 2010. ,
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection, Ann Rheum Dis, vol.68, pp.777-783, 2009. ,
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general, Ann Rheum Dis, vol.70, pp.25-31, 2011. ,
Seronegative spondyloarthropathies: evolving concepts regarding diagnosis and treatment, J Spine, vol.1, p.102, 2012. ,
Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS, Rheumatology (Oxford), vol.54, pp.633-640, 2015. ,
The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study, Ann Rheum Dis, vol.74, pp.1373-1378, 2015. ,
Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis, Ann Rheum Dis, vol.74, pp.65-73, 2015. ,
Ocular manifestations of seronegative spondyloarthropathies, Curr Opin Ophthalmol, vol.25, pp.495-501, 2014. ,
, Biologics and HLA-B27-associated Ocular Disorders
HLA-B27-associated uveitis: overview and current perspectives, Curr Opin Ophthalmol, vol.14, pp.378-383, 2003. ,
Acute anterior uveitis and HLA-B27, Surv Ophthalmol, vol.50, pp.364-388, 2005. ,
HLA-B27-associated uveitis and cystoid macular edema, Ocul Immunol Inflamm, vol.9, pp.177-183, 2001. ,
Posterior segment inflammation in HLA-B27+ acute anterior uveitis: clinical characteristics, Ocul Immunol Inflamm, vol.7, pp.85-92, 1999. ,
Potential Predictors of Poor Visual Outcome in Human Leukocyte Antigen-B27-Associated Uveitis, Am J Ophthalmol, vol.165, pp.179-187, 2016. ,
What is new HLA-B27 acute anterior uveitis?, Ocul Immunol Inflamm, vol.19, pp.139-144, 2011. ,
,
, Rev Rhum Ed Fr, vol.60, pp.81-83, 1993.
Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis, Eye (Lond), vol.14, pp.340-343, 2000. ,
Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period, J Rheumatol, vol.30, pp.1277-1279, 2003. ,
Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches, Arthritis Res, vol.4, pp.307-321, 2002. ,
Anti-TNFalpha agents and methotrexate in spondyloarthritis related uveitis in a Chinese population, Clin Rheumatol, vol.34, pp.1913-1920, 2015. ,
Methotrexate: an option for preventing the recurrence of acute anterior uveitis, Eye (Lond), vol.23, pp.1130-1133, 2009. ,
Interferon-gamma regulates discordant mechanisms of uveitis versus joint and axial disease in a murine model resembling spondylarthritis, Arthritis Rheum, vol.64, pp.762-771, 2012. ,
Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry, MAbs, vol.5, pp.621-623, 2013. ,
FDA approves biosimilar version of infliximab, Am J Health Syst Pharm, vol.73, pp.604-606, 2016. ,
Re)defining biopharmaceutical, Nat Biotechnol, vol.26, pp.743-751, 2008. ,
Biopharmaceuticals and biotechnology medicines: an issue of nomenclature, Eur J Pharm Sci, vol.15, pp.135-138, 2002. ,
Update on the use of systemic biologic agents in the treatment of noninfectious uveitis, Biologics, vol.8, pp.67-81, 2014. ,
Defining the difference: What Makes Biologics Unique, Biotechnol Healthc, vol.1, pp.24-29, 2004. ,
, International nonproprietary names (INN) for biological and biotechnological substances (a review), 2016.
Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders, Ophthalmology, vol.121, pp.785-796, 2014. ,
Binding and functional comparisons of two types of tumor necrosis factor antagonists, J Pharmacol Exp Ther, vol.301, pp.418-426, 2002. ,
Long-term treatment with golimumab for severe uveitis, Ocul Immunol Inflamm, vol.22, pp.90-95, 2014. ,
Golimumab for the treatment of refractory juvenile idiopathic arthritisassociated uveitis, J Ophthalmic Inflamm Infect, vol.2, pp.231-233, 2012. ,
Behcet disease-associated uveitis successfully treated with golimumab, Ocul Immunol Inflamm, vol.21, pp.160-162, 2013. ,
Golimumab treatment for complicated uveitis, Clin Exp Rheumatol, vol.31, pp.320-321, 2013. ,
Golimumab for uveitis, Ophthalmology, vol.118, p.1892, 2011. ,
Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis, Drugs, vol.74, pp.999-1016, 2014. ,
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study, Ann Rheum Dis, vol.73, pp.39-47, 2014. ,
Certolizumab pegol, a new anti-TNF-alpha in the armamentarium against ocular inflammation, Ocul Immunol Inflamm, vol.2015, pp.1-6 ,
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent, N Engl J Med, vol.345, pp.1098-1104, 2001. ,
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for, Rheumatology Biologics Register ,
, Ann Rheum Dis, vol.69, pp.522-528, 2009.
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry, Arthritis Rheum, vol.60, pp.1884-1894, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00618680
The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha antagonist: A metaanalysis of both randomized controlled trials and registry/cohort studies, J Rheumatol, vol.42, pp.2229-2237, 2015. ,
Optic neuritis occurring with anti-tumour necrosis factor alpha therapy, Ann Rheum Dis, vol.66, pp.1255-1258, 2007. ,
TNF inhibitors for uveitis: balancing efficacy and safety, Ocul Immunol Inflamm, vol.18, pp.421-423, 2010. ,
Tumor necrosis factor-alpha antagonists and neuropathy, Muscle Nerve, vol.37, pp.281-292, 2008. ,
Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors, Mult Scler, 2011. ,
Adalimumab-associated multiple sclerosis, J Rheumatol, vol.34, pp.239-240, 2007. ,
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies, Rheumatology (Oxford), vol.49, pp.2217-2219, 2010. ,
, Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy, 2015.
,
, Ocular Immunology & Inflammation
Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?, Immunotherapy, vol.7, pp.353-361, 2015. ,
Anti-TNF-induced lupus, Rheumatology (Oxford), vol.48, pp.716-720, 2009. ,
Immunogenicity and autoimmunity during anti-TNF therapy, Autoimmun Rev, vol.12, pp.703-708, 2013. ,
Evidence that antitumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report, Arthritis Rheum, vol.52, pp.61-72, 2005. ,
Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behcet's disease with infliximab, Graefes Arch Clin Exp Ophthalmol, vol.250, pp.1081-1087, 2012. ,
Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis, Rheumatology (Oxford), vol.50, pp.1445-1452, 2011. ,
Sarcoid-related uveitis occurring during etanercept therapy, Clin Exp Rheumatol, vol.21, pp.645-646, 2003. ,
Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab, J Rheumatol, vol.34, pp.2313-2314, 2007. ,
Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases, Rheumatology (Oxford), vol.48, pp.883-886, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00465169
Relapse of sarcoidosis upon treatment with etanercept, Ann Rheum Dis, vol.67, pp.896-898, 2008. ,
Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?, Clin Exp Rheumatol, vol.30, pp.700-706, 2012. ,
Do tumor necrosis factor inhibitors cause uveitis? A registry-based study, Arthritis Rheum, vol.56, pp.3248-3252, 2007. ,
Do TNF-blockers reduce or induce uveitis?, Rheumatology (Oxford), vol.47, pp.731-732, 2008. ,
Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by, Arthritis Rheum, vol.58, pp.1556-1557, 2008. ,
Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment, Curr Eye Res, vol.35, pp.751-756, 2010. ,
Does etanercept induce uveitis?, Br J Ophthalmol, vol.87, p.925, 2003. ,
Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature, Ocul Immunol Inflamm, vol.14, pp.145-150, 2006. ,
Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary?, J Rheumatol, vol.30, p.2727, 2003. ,
Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors, Ann Rheum Dis, vol.62, pp.88-89, 2003. ,
Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors, Ann Rheum Dis, vol.64, pp.962-964, 2005. ,
Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis, Ann Rheum Dis, vol.61, p.470, 2002. ,
Anti-tumor necrosis factoralpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis, Ophthalmology, vol.109, pp.2342-2346, 2002. ,
Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study, Ann Rheum Dis, vol.68, pp.696-701, 2009. ,
Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review, Clin Exp Rheumatol, vol.32, pp.864-868, 2014. ,
Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series, Clin Experiment Ophthalmol, vol.42, pp.392-395, 2014. ,
Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience, Mediators Inflamm, p.717598, 2014. ,
AB0747 Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 9 patients, Annals of the Rheumatic Diseases, vol.74, p.1149, 2015. ,
Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study, Ann Rheum Dis, vol.65, pp.1631-1634, 2006. ,
Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept, Arthritis Rheum, vol.52, pp.2447-2451, 2005. ,
Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database, Curr Med Res Opin, vol.30, pp.2515-2521, 2014. ,
Etanercept and uveitis: friends or foes, Curr Med Res Opin, vol.31, pp.251-252, 2015. ,
Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis, Arthritis Care Res (Hoboken), vol.68, pp.838-844, 2016. ,
Anti-tumor necrosis factor-alpha agents in noninfectious uveitis, Dev Ophthalmol, vol.51, pp.63-78, 2012. ,
Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis, BMC Musculoskelet Disord, vol.16, p.19, 2015. ,
Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis, Ann Rheum Dis, vol.65, pp.1572-1577, 2006. ,
Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study, Ann Rheum Dis, vol.64, pp.1568-1575, 2005. ,
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis, Arthritis Rheum, vol.48, pp.1667-1675, 2003. ,
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial, Arthritis Rheum, vol.48, pp.3230-3236, 2003. ,
Spondyloarthritis: from unifying concepts to improved treatment, Rheumatology (Oxford), vol.53, pp.1547-1559, 2014. ,
The interleukin-23/ interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis, Curr Opin Rheumatol, vol.26, pp.361-370, 2014. ,
Pathophysiology of ankylosing spondylitis: what's new?, Joint Bone Spine, vol.75, pp.656-660, 2008. ,
Elevated serum levels of interleukin-17A in uveitis patients, Ocul Immunol Inflamm, vol.21, pp.434-439, 2013. ,
TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1, Nat Med, vol.13, pp.711-718, 2007. ,
Treatment of spondyloarthritis beyond TNF-alpha blockade, Best Pract Res Clin Rheumatol, vol.28, pp.819-827, 2014. ,
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis, Sci Transl Med, vol.2, pp.52-72, 2010. ,
Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology, vol.120, pp.777-787, 2013. ,
Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy ,
, Ophthalmology, vol.122, pp.939-948, 2015.
an Interleukin-17A Inhibitor, in Ankylosing Spondylitis, N Engl J Med, vol.373, pp.2534-2548, 2015. ,
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial, Lancet, vol.382, pp.1705-1713, 2013. ,
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis, N Engl J Med, vol.373, pp.1329-1339, 2015. ,
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, doubleblind, placebo-controlled, phase 3 trial, Lancet, vol.386, pp.1137-1146, 2015. ,
Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study, Ann Rheum Dis, vol.63, pp.1041-1045, 2004. ,
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks, Ann Rheum Dis, vol.64, pp.296-298, 2005. ,
Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebocontrolled trials, Ann Rheum Dis, vol.73, pp.95-100, 2014. ,
Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind ,
, Ann Rheum Dis, vol.74, pp.1051-1057, 2015.
Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis, Ocul Immunol Inflamm, vol.19, pp.382-383, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01183023
Tocilizumab in severe and refractory non-infectious uveitis, Clin Exp Rheumatol, vol.32, pp.75-79, 2014. ,
Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema, Ophthalmology, vol.121, pp.2380-2386, 2014. ,
Tocilizumab treatment for refractory uveitis-related cystoid macular edema, Graefes Arch Clin Exp Ophthalmol, vol.251, pp.2627-2632, 2013. ,
Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report, Graefes Arch Clin Exp Ophthalmol, vol.252, pp.163-164, 2014. ,
A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab, Mod Rheumatol, vol.22, pp.298-302, 2012. ,
Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review, Clin Exp Rheumatol, vol.32, pp.54-57, 2014. ,
Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect?, J Rheumatol, vol.38, p.2284, 2011. ,
Different response to rituximab in tumor necrosis factor blockernaive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial, Arthritis Rheum, vol.62, pp.1290-1297, 2010. ,
Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study, Ann Rheum Dis, vol.70, pp.1108-1110, 2011. ,
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial, Arthritis Rheum, vol.63, pp.939-948, 2011. ,
Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory?, Curr Opin Rheumatol, vol.24, pp.351-358, 2012. ,